Search

Your search keyword '"Cortes, Jorge E."' showing total 16 results
Start Over Author "Cortes, Jorge E." Journal leukemia research
16 results on '"Cortes, Jorge E."'

2. Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Author

Mughal, Tariq I, Gotlib, Jason, Mesa, Ruben, Koschmieder, Steffen, Khoury, H Jean, Cortes, Jorge E, Barbui, Tiziano, Hehlmann, Rüdiger, Mauro, Michael, Saussele, Susanne, Radich, Jerald P, Van Etten, Richard A, Saglio, Giuseppe, Verstovek, Srdnan, Gale, Robert Peter, and Abdel-Wahab, Omar

Subjects
Humans, Mastocytosis, Systemic, Cell Transformation, Neoplastic, Cardiovascular Diseases, Myeloproliferative Disorders, Chronic Disease, Staurosporine, Calreticulin, Fusion Proteins, bcr-abl, Antineoplastic Agents, Protein Kinase Inhibitors, Remission Induction, Epigenesis, Genetic, Mutation, Janus Kinase 2, Congresses as Topic, Translational Medical Research, CALR, CML, Cardiotoxicity, JAK2 inhibitors, MPN, Mastocytosis, TFR, Systemic, Cell Transformation, Neoplastic, Fusion Proteins, bcr-abl, Epigenesis, Genetic, Immunology, Clinical Sciences
Abstract

This review is based on the presentations and deliberations at the 7th John Goldman Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN) Colloquium which took place in Estoril, Portugal on the 15th October 2017, and the 11th post-ASH International Workshop on CML and MPN which took place on the 6th-7th December 2016, immediately after the 58th American Society of Hematology Annual Meeting. Rather than present a resume of the proceedings, we have elected to address some of the topical translational research and clinically relevant topics in greater detail. We address recent updates in the genetics and epigenetics of MPN, the mechanisms of transformation by mutant calreticulin, advances in the biology and therapy of systemic mastocytosis, clinical updates on JAK2 inhibitors and other therapeutic approaches for patients with MPNs, cardiovascular toxicity related to tyrosine kinase inhibitors and the concept of treatment-free remission for patients with CML.

Published
2018

4. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study

Author

Swords, Ronan T., Greenberg, Peter L., Wei, Andrew H., Durrant, Simon, Advani, Anjali S., Hertzberg, Mark S., Lewis, Ian D., Rivera, Gabriel, Gratzinger, Dita, Fan, Alice C., Felsher, Dean W., Cortes, Jorge E., Watts, Justin M., Yarranton, Geoff T., Walling, Jackie M., and Lancet, Jeffrey E.

Published
2016
Full Text
View/download PDF

10. Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes

Author

Giles, Francis J., Kantarjian, Hagop M., Cortes, Jorge E., Faderl, Stephan, Verstovsek, Srdan, Thomas, Deborah, Garcia-Manero, Guillermo, Wierda, William, Ferrajoli, Alessandra, Kornblau, Stephen, Mattiuzzi, Gloria N., Tsimberidou, Apostolia M., Albitar, Maher, O’Brien, Susan M., and Estey, Elihu

Published
2005
Full Text
View/download PDF

12. Phase I and pharmacodynamic study of Triapine ®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

Author

Giles, Francis J., Fracasso, Paula M., Kantarjian, Hagop M., Cortes, Jorge E., Brown, Randy A., Verstovsek, Srdan, Alvarado, Yesid, Thomas, Deborah A., Faderl, Stefan, Garcia-Manero, Guillermo, Wright, Lisa P., Samson, Tom, Cahill, Ann, Lambert, Paula, Plunkett, William, Sznol, Mario, DiPersio, John F., and Gandhi, Varsha

Published
2003
Full Text
View/download PDF

14. Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]

Author

Swords, Ronan T., primary, Greenberg, Peter L., additional, Wei, Andrew H., additional, Durrant, Simon, additional, Advani, Anjali S., additional, Hertzberg, Mark S., additional, Lewis, Ian D., additional, Rivera, Gabriel, additional, Gratzinger, Dita, additional, Fan, Alice C., additional, Felsher, Dean W., additional, Cortes, Jorge E., additional, Watts, Justin M., additional, Yarranton, Geoff T., additional, Walling, Jackie M., additional, and Lancet, Jeffrey E., additional

Published
2017
Full Text
View/download PDF

15. Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

Author

Giles, Francis J., primary, Fracasso, Paula M., additional, Kantarjian, Hagop M., additional, Cortes, Jorge E., additional, Brown, Randy A., additional, Verstovsek, Srdan, additional, Alvarado, Yesid, additional, Thomas, Deborah A., additional, Faderl, Stefan, additional, Garcia-Manero, Guillermo, additional, Wright, Lisa P., additional, Samson, Tom, additional, Cahill, Ann, additional, Lambert, Paula, additional, Plunkett, William, additional, Sznol, Mario, additional, DiPersio, John F., additional, and Gandhi, Varsha, additional

Published
2003
Full Text
View/download PDF

16. Phase I and pharmacodynamic study of Triapine®, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia

Author

Giles, Francis J., Fracasso, Paula M., Kantarjian, Hagop M., Cortes, Jorge E., Brown, Randy A., Verstovsek, Srdan, Alvarado, Yesid, Thomas, Deborah A., Faderl, Stefan, Garcia-Manero, Guillermo, Wright, Lisa P., Samson, Tom, Cahill, Ann, Lambert, Paula, Plunkett, William, Sznol, Mario, DiPersio, John F., and Gandhi, Varsha

Subjects
*LEUKEMIA, *RIBONUCLEOSIDE diphosphate reductase, *INTRAVENOUS therapy
Abstract

In a phase I study, 24 patients with refractory leukemia received Triapine®, a novel ribonucleotide reductase (RR) inhibitor, as a continuous intravenous infusion over 96 h beginning on days 1 and 15 or days 1 and 8. On the days 1 and 15 regimen, the starting dose was 120 mg/m2 per day, and the maximum tolerated dose (MTD) was 160 mg/m2 per day. Three of eight patients receiving 160 mg/m2 per day in the first course, and one patient escalated to this dose in a second course, developed hepatic dose-limiting toxicity (DLT). For the days 1 and 8 regimen, the first 96 h infusion was administered at a fixed dose of 140 mg/m2 per day. The dose of the second infusion beginning on day 8 was escalated from 120 to 160 mg/m2 per day without observing DLT. No objective responses occurred. Over 70% of patients had a >50% reduction in white blood cell counts. The steady-state levels of Triapine were between 0.6 and 1 μM. As expected from the in vitro studies, at these plasma concentrations there was a decline in dATP and dGTP pools and a decrease in DNA synthetic capacity of the circulating leukemia cells. Based on these clinical, pharmacokinetic, and pharmacodynamic data, Triapine warrants further study in patients with hematologic malignancies. [Copyright &y& Elsevier]

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results